Published in Mol Immunol on July 28, 2005
Systemic inflammation, metabolic syndrome and progressive renal disease. Nephrol Dial Transplant (2009) 1.63
The connection between C-reactive protein and atherosclerosis. Ann Med (2008) 1.29
C-reactive protein-bound enzymatically modified low-density lipoprotein does not transform macrophages into foam cells. J Immunol (2008) 1.21
Pattern recognition by pentraxins. Adv Exp Med Biol (2009) 1.19
Phosphoethanolamine-complexed C-reactive protein: a pharmacological-like macromolecule that binds to native low-density lipoprotein in human serum. Clin Chim Acta (2008) 1.06
Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk. Vasc Health Risk Manag (2009) 0.86
Oct-1 acts as a transcriptional repressor on the C-reactive protein promoter. Mol Immunol (2012) 0.84
Targeting C-Reactive Protein in Inflammatory Disease by Preventing Conformational Changes. Mediators Inflamm (2015) 0.80
Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe. Lipids Health Dis (2013) 0.79
Effects of simvastatin on proinflammatory cytokines and matrix metalloproteinases in hypercholesterolemic individuals. Inflammation (2011) 0.79
Effect of wine phenolics on cytokine-induced C-reactive protein expression. J Thromb Haemost (2007) 0.78
A novel RBP-J kappa-dependent switch from C/EBP beta to C/EBP zeta at the C/EBP binding site on the C-reactive protein promoter. J Immunol (2007) 0.78
Therapeutic potential of phosphoethanolamine-bound C-reactive protein in atherosclerosis. Future Lipidol (2008) 0.77
Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem (1982) 27.26
C-reactive protein levels and outcomes after statin therapy. N Engl J Med (2005) 9.47
Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med (2005) 4.64
C-reactive Protein. J Biol Chem (2004) 4.39
Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology (1990) 3.27
Hepatocytes produce nitrogen oxides from L-arginine in response to inflammatory products of Kupffer cells. J Exp Med (1989) 2.49
Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. Proc Natl Acad Sci U S A (1993) 2.46
Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med (2004) 2.39
Statins and the acute-phase response. N Engl J Med (2001) 2.28
C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A (2002) 2.20
Control of the acute phase response. Demonstration of C-reactive protein synthesis and secretion by hepatocytes during acute inflammation in the rabbit. J Exp Med (1978) 2.10
Novel effects of nitric oxide. Annu Rev Pharmacol Toxicol (2001) 2.08
CRP after 2004. Mol Immunol (2004) 1.91
Nitric oxide and the regulation of gene expression. Trends Cell Biol (2001) 1.76
Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol (1999) 1.74
STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J Biol Chem (1996) 1.68
Effect of combinations of cytokines and hormones on synthesis of serum amyloid A and C-reactive protein in Hep 3B cells. J Immunol (1991) 1.60
Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood (2002) 1.60
Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. J Biol Chem (2004) 1.55
Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol (2005) 1.49
Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Lond) (2000) 1.44
Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. Biochim Biophys Acta (1991) 1.38
Potential cardioprotective actions of no-releasing aspirin. Nat Rev Drug Discov (2002) 1.33
Overexpressed nuclear factor-kappaB can participate in endogenous C-reactive protein induction, and enhances the effects of C/EBPbeta and signal transducer and activator of transcription-3. Immunology (2003) 1.33
Possible protective role for C-reactive protein in atherogenesis: complement activation by modified lipoproteins halts before detrimental terminal sequence. Circulation (2004) 1.26
Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice. Arterioscler Thromb Vasc Biol (2004) 1.22
Regulation of human C-reactive protein gene expression by two synergistic IL-6 responsive elements. Biochemistry (1996) 1.18
A C-reactive protein mutant that does not bind to phosphocholine and pneumococcal C-polysaccharide. J Immunol (2002) 1.14
Transactivation of C-reactive protein by IL-6 requires synergistic interaction of CCAAT/enhancer binding protein beta (C/EBP beta) and Rel p50. J Immunol (2001) 1.12
The Rel family member P50 mediates cytokine-induced C-reactive protein expression by a novel mechanism. J Immunol (2000) 1.11
Transcription factor c-Rel enhances C-reactive protein expression by facilitating the binding of C/EBPbeta to the promoter. Mol Immunol (2003) 1.09
A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood (1996) 1.07
Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am J Physiol Heart Circ Physiol (2004) 1.04
Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, and atherogenesis in hypercholesterolemic mice. Proc Natl Acad Sci U S A (2002) 1.04
Regulation of cytokine-induced human C-reactive protein production by transforming growth factor-beta. J Immunol (1990) 1.03
Nitric oxide donors. Proc Soc Exp Biol Med (2000) 1.03
The effect of interleukin-1 on C-reactive protein expression in Hep3B cells is exerted at the transcriptional level. Biochem J (1995) 1.02
CRP or not CRP? That is the question. Arterioscler Thromb Vasc Biol (2005) 1.00
Interaction of calcium-bound C-reactive protein with fibronectin is controlled by pH: in vivo implications. J Biol Chem (2004) 1.00
C-reactive protein levels determine systemic nitric oxide bioavailability in patients with coronary artery disease. Eur Heart J (2004) 0.95
Inducible nitric oxide synthase expression and erythropoietin production in human hepatocellular carcinoma cells. Biochem Biophys Res Commun (1997) 0.84
Gut function and immune and inflammatory responses in patients perioperatively fed with supplemented enteral formulas. Arch Surg (1996) 0.84
L-arginine rescues decreased erythropoietin gene expression by stimulating GATA-2 with L-NMMA. Kidney Int (2002) 0.81
AMPK activation may suppress hepatic production of C-reactive protein by stimulating nitric oxide synthase. Med Hypotheses (2004) 0.79
Atherosclerosis and nitric oxide production. Circulation (2000) 0.77
C-reactive protein and atherosclerosis. Science (2002) 0.77
A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract (2003) 2.32
Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kappaB and C/EBPbeta activation. J Biol Chem (2007) 1.69
High HIV burden among people who inject drugs in 15 Indian cities. AIDS (2015) 1.60
The connection between C-reactive protein and atherosclerosis. Ann Med (2008) 1.29
C-reactive protein-bound enzymatically modified low-density lipoprotein does not transform macrophages into foam cells. J Immunol (2008) 1.21
Regulation of basal and induced expression of C-reactive protein through an overlapping element for OCT-1 and NF-kappaB on the proximal promoter. J Immunol (2005) 1.13
Structural and functional anatomy of the globular domain of complement protein C1q. Immunol Lett (2004) 1.11
Lomotil dependence: a note of caution. Natl Med J India (2006) 1.06
Phosphoethanolamine-complexed C-reactive protein: a pharmacological-like macromolecule that binds to native low-density lipoprotein in human serum. Clin Chim Acta (2008) 1.06
Interaction of C1q with IgG1, C-reactive protein and pentraxin 3: mutational studies using recombinant globular head modules of human C1q A, B, and C chains. Biochemistry (2006) 1.05
Binding of the monomeric form of C-reactive protein to enzymatically-modified low-density lipoprotein: effects of phosphoethanolamine. Clin Chim Acta (2009) 1.05
Role of the property of C-reactive protein to activate the classical pathway of complement in protecting mice from pneumococcal infection. J Immunol (2006) 1.01
Interaction of calcium-bound C-reactive protein with fibronectin is controlled by pH: in vivo implications. J Biol Chem (2004) 1.00
Identification of acidic pH-dependent ligands of pentameric C-reactive protein. J Biol Chem (2010) 0.96
Can glycohemoglobin be used to assess glycemic control in patients with chronic renal failure? Clin Chem (2002) 0.92
Delivery models of opioid agonist maintenance treatment in South Asia: a good beginning. Bull World Health Organ (2013) 0.89
The phosphocholine and the polycation-binding sites on rabbit C-reactive protein are structurally and functionally distinct. Mol Immunol (2003) 0.88
Exposing a hidden functional site of C-reactive protein by site-directed mutagenesis. J Biol Chem (2011) 0.86
Scale-up of opioid substitution therapy in India: opportunities and challenges. Int J Drug Policy (2012) 0.85
Oct-1 acts as a transcriptional repressor on the C-reactive protein promoter. Mol Immunol (2012) 0.84
The binding of C-reactive protein, in the presence of phosphoethanolamine, to low-density lipoproteins is due to phosphoethanolamine-generated acidic pH. Clin Chim Acta (2009) 0.81
The phosphocholine-binding pocket on C-reactive protein is necessary for initial protection of mice against pneumococcal infection. J Biol Chem (2012) 0.81
CRP can play both pro-inflammatory and anti-inflammatory roles. Mol Immunol (2006) 0.80
A novel RBP-J kappa-dependent switch from C/EBP beta to C/EBP zeta at the C/EBP binding site on the C-reactive protein promoter. J Immunol (2007) 0.78
Type of opioids injected: does it matter? A multicentric cross-sectional study of people who inject drugs. Drug Alcohol Rev (2014) 0.78
Computational analysis of C-reactive protein for assessment of molecular dynamics and interaction properties. Cell Biochem Biophys (2013) 0.76
Diagnostic dilemma: A case of self-injurious behavior. Indian J Psychiatry (2011) 0.75
India's National Narcotic Drugs and Psychotropic Substances policy, 2012: a 20th century document in the 21st century. Int J Drug Policy (2013) 0.75